In order to produce a future assay, it is necessary to transfer the chemistry to a suitable material surface. This chemistry has been shown to effective in serum. We have studied the concentration-dependant break up of the gelsolin-actin-rhodamine complex at LPA concentrations of biological significance (1-50 micromolar).

The design of our assay is based upon the highly selective disruption of the binding of gelsolin to the protein actin by LPA, which is signalled via a rhodamine dye. We are in the process of developing both a simple screening assay, and a biosensor technique specially desigend for the clinical biochemistry lab for LPA. Currently, there is no simple screening assay for this molecule in serum or blood.

Our technology involves the biomarker, lysophosphatic acid (LPA), which has clearly been shown to be present in the early stages of disease.

Accordingly, there is an urgent requirement for a srreening assay that can detect the presence of ovarian or fallopian tube tumours at the early stage of the dieease via biomarker technology. The existing CA-125 assay for ovarian cancer has been used for many years but is widely regarded to be inadequate ,especially for detection of early development of the disease (stages I and II). He was made a Fellow of the Royal Society of Canada in 1999. He served on the Editorial Boards of majour journals and is currently Editor in Chief of the Royal Society of Chemistry book series on Detection Science. He has published close to 300 papers in international journals and has received many prestiguous awards for his research. He is Professor of Bioanalytical Chemistry in both the Department of Chemistry and Institute for Biomedical Engineering at the University of Toronto. Michael Thompson has obtained his PhD from McMaster Ujniversity in Hamilton, Ontario.

Medical conferences 2016 uk